Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers

Inclusion Criteria: * Healthy male age 18-45 * Body mass index (BMI) 18-30 kg/m2 * Male subjects or their partners must use an adequate method of contraception at all times during the study. * Negative laboratory tests for HIV, HBcAb and HCV at the screening visit * Naïve to any previous recombinant protein therapy * Provide written informed consent * Have the ability to understand the requirements of the study and to comply with the study protocol and dosing regimen Exclusion Criteria: * Clinical evidence of any active significant disease that could potentially compromise the ability of the Investigator to evaluate or interpret the effects of the study treatment on safety assessment, thus increasing the risk to the subject to unacceptable levels * Presence of any acute or chronic diseases * History of any allergies or protein-drug hypersensitivity * Exposure to long-term steroid treatment within the last 12 months prior to the study * Subject had a major operation in last 6 months * Subject has received immunosuppressive treatment prior to the study * Chronic use of any medication including vitamins * Participation in another clinical trial during the previous 3 months (subject report) * Reported history of alcohol or drug abuse * Subjects with short bowel (more than 1 m removed of small bowel).